We first compared the anti-tumor activity of CD33 CAR T cells against AML and B-ALL cell lines that were engineered to express equivalent levels of CD33 (U937CD33 and Nalm6CD33) (Fig. 1A). This evidence concerns the gene CD33 and acute lymphoblastic leukemia.